ARS Pharmaceuticals

ARS markets Neffy, a needle-free intranasal epinephrine spray for severe allergic reactions, offering a faster and more convenient alternative.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2022
Stage of Initial Investment
Series D
Initial Investment Year
2021